Compare Charles River Laboratories Intl. Inc (CRL) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs PepsiCo, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $226.38 (market cap $11.14B), while PepsiCo, Inc. trades at $135.99 (market cap $184.87B). The key difference: PepsiCo, Inc. is far larger — about 16.6× Charles River Laboratories Intl. Inc's market cap, and PepsiCo, Inc. pays a 4.37% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | PEP | |
|---|---|---|
Market Cap | $11.14B | $184.87B |
Sector | Health | Consumer Staples |
52-Week High | $233.60 | $170.44 |
52-Week Low | $145.57 | $133.81 |
Enterprise Value | $14.00B | $227.37B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
PepsiCo (PEP) trades at $135.75, down 1.98% on the day, with a bearish technical signal and support near $132. The company reported revenue of $93.93B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while analysts expect in-line Q1 2026 results.
The stock offers a dividend yield near 4% and trades below the consensus price target of $159.27, suggesting upside potential. Risks include competitive pressures and execution of the North American turnaround. Wall Street sentiment is mixed, with 33% buy ratings but a majority hold consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
